SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

MLA

Sarah Halford, et al. “SPIKE-1: A Randomised Phase II/III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-Initiated Membrane Fusion.” Trials, vol. 22, no. 1, Aug. 2021, pp. 1–3. EBSCOhost, https://doi.org/10.1186/s13063-021-05461-9.

APA

Sarah Halford, Susan Wan, Ilaria Dragoni, Julie Silvester, Bobojon Nazarov, Daniel Anthony, Suzie Anthony, Emma Ladds, John Norrie, Kevin Dhaliwal, & the CDD SPIKE-1 Project Team. (2021). SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. Trials, 22(1), 1–3. https://doi.org/10.1186/s13063-021-05461-9

Chicago

Sarah Halford, Susan Wan, Ilaria Dragoni, Julie Silvester, Bobojon Nazarov, Daniel Anthony, Suzie Anthony, et al. 2021. “SPIKE-1: A Randomised Phase II/III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-Initiated Membrane Fusion.” Trials 22 (1): 1–3. doi:10.1186/s13063-021-05461-9.